Regulatory T cells and autoimmune disease

Authors

  • Silke Paust,

    1. Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Boston, MA, USA.
    2. Department of Pathology, Harvard Medical School, Boston, MA, USA.
    Search for more papers by this author
  • Harvey Cantor

    Corresponding author
    1. Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Boston, MA, USA.
    2. Department of Pathology, Harvard Medical School, Boston, MA, USA.
    Search for more papers by this author

* Harvey Cantor
44 Binney Street
Boston, MA 02115, USA
Tel.: +1 617 6323348
Fax: +1 617 6324630
E-mail: harvey_cantor@dfci.harvard.edu

Abstract

Summary:  Although T-cell clones bearing T-cell receptors with high affinity for self-peptide major histocompatibility complex (MHC) products are generally eliminated in the thymus (recessive tolerance), the peripheral T-cell repertoire remains strongly biased toward self-peptide MHC complexes and includes autoreactive T cells. A search for peripheral T cells that might exert dominant inhibitory effects on autoreactivity has implicated a subpopulation of CD4+CD25+ T cells called regulatory T cells (Tregs). Here, we discuss the role of cytokines and costimulatory molecules in the generation, maintenance, and function of Tregs. We also summarize evidence for the involvement of Tregs in controlling autoimmune diseases, including type 1 diabetes, experimental autoimmune encephalomyelitis, and inflammatory bowel disease. Last, we discuss our recent definition of the potential role of B7 expressed on activated T-effector cells as a target molecule for Treg-dependent suppression. These observations suggest that the engagement of B7 on effector T cells transmits an inhibitory signal that blocks or attenuates effector T-cell function. We restrict our comments to the suppression mediated by cells within the CD4 lineage; the impact of the cells within the CD8 lineage that may suppress via engagement of Qa-1 on effector T cells is not addressed in this review.

Ancillary